Compare TOUR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | IMMP |
|---|---|---|
| Founded | 2006 | 1987 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.1M | 61.4M |
| IPO Year | 2014 | 2012 |
| Metric | TOUR | IMMP |
|---|---|---|
| Price | $5.10 | $0.44 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 16.9K | ★ 439.9K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.30 | $445.09 |
| Revenue Next Year | $14.00 | N/A |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.29 |
| 52 Week High | $7.79 | $3.53 |
| Indicator | TOUR | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 51.93 |
| Support Level | $4.53 | $0.42 |
| Resistance Level | $6.50 | $0.56 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 40.17 | 74.89 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.